Papers/PMID:38654355
A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.
Virology journal2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
magnesium(2+) — no detected effect on hospital length of stay
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The average duration of hospital stay did not show any significant difference between the magnesium group and control group (7.32 ± 5.37 days vs. 7.28 ± 4.65 days; P = 0.84).”
Quoted verbatim from A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.. - Study
- RCT
- Participants
- 60
- Dose
- 300 mg daily as magnesium citrate capsules, from admission to discharge
- Population
- Hospitalised adults aged 18-70 with moderate COVID-19 (60 analysed, 30 per arm)
A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.2024PMID:38654355Permalink